Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model
- 470 Downloads
Accumulating evidence indicates that bead-based artificial antigen-presenting cells (aAPCs) are a powerful tool to induce antigen-specific T cell responses in vitro and in vivo. To date, most conventional aAPCs have been generated by coupling an antigen signal (signal 1) and one or two costimulatory signals, such as anti-CD28 with anti-LFA1 or anti-4-1BB (signal 2), onto the surfaces of cell-sized or nanoscale magnetic beads or polyester latex beads. The development of a biodegradable scaffold and the combined use of multiple costimulatory signals as well as third signals for putative clinical applications is the next step in the development of this technology. Here, a novel biodegradable aAPC platform for active immunotherapy was developed by co-encapsulating IL-2 and anti-CTLA-4 inside cell-sized polylactic-co-glycolic acid microparticles (PLGA-MPs) while co-coupling an H-2Kb/TRP2-Ig dimer and anti-CD28 onto the surface. Cytokines (activating signal) and antibodies (anti-inhibition signal) were efficiently co-encapsulated in PLGA-MP-based aAPCs and co-released without interfering with each other. The targeted, sustained co-release of IL-2 and anti-CTLA-4 achieved markedly enhanced, synergistic effects in activating and expanding tumor antigen-specific T cells both in vitro and in vivo, as well as in inhibiting tumor growth in a mouse melanoma model, as compared with conventional two-signal aAPCs and IL-2 or anti-CTLA-4 single-released aAPCs. These data revealed the feasibility and importance of the paracrine release of multiple costimulatory molecules and cytokines from biodegradable aAPCs and thus provide a proof of principle for the future use of polymeric aAPCs for active immunotherapy of tumors and infectious diseases.
KeywordsArtificial antigen-presenting cells PLGA-MPs IL-2 Anti-CTLA-4 Active immunotherapy
Artificial antigen-presenting cells
Micro- and nanoparticles
Peptide-major histocompatibility complex
Tyrosinase-related protein 2
This work was supported by the National Natural Science Foundation of China (81172823, 81372448) and the Science and Technology Support Program of Jiangsu Province (BE2012739).
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 4.Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK (2015) Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. J Immunother 38(4):155–164. doi: 10.1097/CJI.0000000000000075 CrossRefPubMedGoogle Scholar
- 11.Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H (2016) Programmed death-ligand 1 on antigen-presenting cells facilitates the induction of antigen-specific cytotoxic T lymphocytes: application to adoptive T-cell immunotherapy. J Immunother 39(8):306–315. doi: 10.1097/CJI.0000000000000136 CrossRefPubMedGoogle Scholar
- 13.Garnier A, Hamieh M, Drouet A, Leprince J, Vivien D, Frebourg T, Le Mauff B, Latouche JB, Toutirais O (2016) Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells. Immunol Cell Biol 94(7):662–672. doi: 10.1038/icb.2016.25 CrossRefPubMedGoogle Scholar
- 16.Perica K, Bieler JG, Schutz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP (2015) Enrichment and expansion with nanoscale artificial antigen presenting cells for adoptive immunotherapy. ACS Nano 9(7):6861–6871. doi: 10.1021/acsnano.5b02829 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP (2009) In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother 58(2):209–220. doi: 10.1007/s00262-008-0542-1 CrossRefPubMedGoogle Scholar
- 24.Shah SR, Henslee AM, Spicer PP, Yokota S, Petrichenko S, Allahabadi S, Bennett GN, Wong ME, Kasper FK, Mikos AG (2014) Effects of antibiotic physicochemical properties on their release kinetics from biodegradable polymer microparticles. Pharm Res 31(12):3379–3389. doi: 10.1007/s11095-014-1427-y CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Donat U, Rother J, Schäfer S, Hess M, Härtl B, Kober C, Langbein-Laugwitz J, Stritzker J, Chen NG, Aguilar RJ (2014) Characterization of metastasis formation and virotherapy in the human C33A cervical cancer model. PLoS One 9(6):e98533. doi: 10.1371/journal.pone.0098533 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Han H, Peng JR, Chen PC, Gong L, Qiao SS, Wang WZ, Cui ZQ, Yu X, Wei YH, Leng XS (2011) A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro. Biochem Biophys Res Commun 411(3):530–535. doi: 10.1016/j.bbrc.2011.06.164 CrossRefPubMedGoogle Scholar